Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy-proven\* relapsed or refractory lymphoma, including the following:~  * Aggressive lymphoma (closed to accrual as of 2/7/08 except for diffuse large B cell lymphoma, grade III follicular lymphoma, or transformed lymphoma)~    * Transformed lymphoma~   * Diffuse large B-cell lymphoma~   * Mantle cell lymphoma~   * Grade 3 follicular lymphoma~   * Precursor B-cell lymphoblastic leukemia/lymphoma~   * Mediastinal (thymic) large B-cell lymphoma~   * Burkitt's lymphoma/leukemia~   * Precursor T-cell lymphoblastic leukemia/lymphoma~   * Primary cutaneous anaplastic large cell lymphoma~   * Primary systemic type anaplastic large cell lymphoma~ * Indolent lymphoma (closed to accrual as of 8/18/08)~    * Small lymphocytic lymphoma/chronic lymphocytic leukemia~   * Grade 1 or 2 follicular lymphoma~   * Extranodal marginal zone B-cell lymphoma of MALT type~   * Nodal marginal zone B-cell lymphoma~   * Splenic marginal zone B-cell lymphoma~ * Uncommon lymphoma (closed to accrual as of 9/2/08)~    * Unspecified peripheral T-cell lymphoma~   * Anaplastic large cell lymphoma (T and null cell type)~   * Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)~   * Central Nervous System (CNS) lymphoma~   * Post-transplant lymphoproliferative disorder~   * Mycosis fungoides/Sezary syndrome~   * Hodgkin's lymphoma~   * Primary effusion lymphoma~   * Blastic Natural Killer(NK)-cell lymphoma~   * Adult T-cell leukemia/lymphoma~   * Nasal type extranodal NK/T-cell lymphoma~   * Enteropathy type T-cell lymphoma~   * Hepatosplenic T-cell lymphoma~   * Subcutaneous panniculitis-like T-cell lymphoma~   * Angioimmunoblastic T-cell lymphoma~NOTE: \*Biopsies performed \< 6 months prior to study entry are allowed; biopsy-proven CNS lymphoma (at any time) does not require a re-biopsy in order to be eligible for this study~* Previously treated disease~  * Patients with aggressive lymphoma (closed to accrual as of 8/24/07) OR Hodgkin's lymphoma must have received or be ineligible for potentially curative therapy, including stem cell transplantation~* Measurable disease\*\* by CT scan or MRI, defined by 1 of the following:~  * At least 1 unidimensionally measurable lesion \> 2 cm in diameter~    * Skin lesions may be used if they meet this criterion and are photographed with a ruler~ * More than 5,000/mm³ tumor cells in the blood~NOTE: \*\*For patients with lymphoplasmacytic lymphoma without measurable lymphadenopathy, measurable disease may be defined by bone marrow lymphoplasmacytosis with \> 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy AND quantitative Immunoglobulin M(IgM) monoclonal protein \> 1,000 mg/dL~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group(ECOG) performance status 0-2~* Life expectancy \> 3 months~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Hemoglobin ≥ 8 g/dL~* Total bilirubin ≤ 2 times upper limit of normal (ULN) OR direct bilirubin ≤ 1.5 times ULN~* aspartate aminotransferase(AST) ≤ 3 times ULN (5 times ULN if liver involvement is present)~* Creatinine ≤ 2 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Willing to provide blood samples and portion of bone marrow aspirate and biopsy during study participation~* Able to swallow intact study medication tablets~* No other life-threatening illness (unrelated to tumor)~* No serious non-malignant disease (e.g., active infection or other condition) that, in the opinion of the investigator, would preclude study participation~* No other active malignancy requiring treatment or that would preclude study participation~* No known HIV positivity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 3 weeks since prior myelosuppressive chemotherapy or biologic therapy (unless the patient has recovered from the nadir of the previous treatment)~* More than 3 weeks since prior radiotherapy (unless the acute side effects associated with therapy are resolved)~* Concurrent stable (i.e., not increased within the past month) chronic doses of corticosteroids, with a maximum dose of 20 mg of prednisone per day, is allowed if prescribed for disorders other than lymphoma (e.g., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or asthma)~  * Non-escalating doses of steroids at the lowest possible dosing level are allowed for CNS lymphoma~* No other concurrent investigational ancillary therapy~* No other concurrent chemotherapy, immunotherapy, or radiotherapy~* No concurrent participation in any other clinical trial involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy) for symptom control or therapeutic intent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Relapsed aggressive non-Hodgkin lymphoma (Type: EXPERIMENTAL): Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
- Relapsed indolent non-Hodgkin lymphoma (Type: EXPERIMENTAL): Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
- Uncommon lymphomas (Type: EXPERIMENTAL): Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.

Based on this trial design, predict the completion outcome and termination type (if applicable).